Kansas State Employee Health Plan raises its GLP-1 BMI threshold to 35

Kansas' State Employee Health Plan (SEHP) has raised the bar for who can get coverage for GLP-1 medications used for weight management. Starting January 1, 2026, members must have a Body Mass Index of 35 or higher to qualify, a rule that applies to all weight-management GLP-1 prescriptions issued or renewed after that date ^[1].

The plan also set a clear pecking order among the drugs. Wegovy is the preferred GLP-1 for weight management under SEHP's formulary. Zepbound is listed as non-preferred, meaning members can only get it covered if they have already tried and failed a preferred product, or if they cannot use it for medical reasons and their provider submits documentation for a review by Caremark, the plan's pharmacy benefit manager ^[1].

All anti-obesity medications already required prior authorization through Caremark, and that will continue. Coverage will need to be re-approved periodically, with documentation showing the drug is still being used and is still working to reduce weight ^[1].

SEHP says the changes are driven by cost. The plan states that the price of covering these drugs has increased significantly in the past year, affecting costs for both the plan and its members, and notes that unlike many other weight-loss options, GLP-1 spending is an ongoing expense with long-term financial impact ^[1]. SEHP says other state employee plans around the country have either dropped GLP-1 coverage entirely or added their own usage guidelines, and it places itself in the latter group ^[1].

Why it matters for patients

For SEHP members currently using or considering a GLP-1 for weight management, the BMI cutoff is now a hard line. A BMI of 35 corresponds to obesity that is more severe than the standard clinical threshold of 30 often used to define obesity, so some members who previously qualified under a lower BMI standard may lose access when their prescription comes up for renewal after January 1, 2026 ^[1].

The preferred-drug requirement also matters for people currently on Zepbound (tirzepatide). Under the new rules, staying on Zepbound with coverage generally requires having already tried and failed Wegovy (semaglutide), or having a documented medical reason they cannot use it, backed by paperwork their provider submits to Caremark for review ^[1]. That means some members may need to switch medications, appeal through their provider, or pay out of pocket to continue their current treatment.

Because prior authorization must be renewed periodically with proof the drug is working, members will need ongoing documentation from their care team, not just an initial approval, to keep coverage in place ^[1].

SEHP frames these changes as part of a broader effort to keep the health plan affordable, pointing to rising costs as demand for these drugs has grown ^[1]. The plan continues to offer non-drug options too, including an eight-week weight management course and individual health coaching sessions through its HealthQuest program with Marathon Health ^[1].

What happens next

The BMI threshold and preferred-drug rules take effect for prescriptions issued or renewed on or after January 1, 2026 ^[1]. Members with questions about how the change affects their specific coverage are directed to their HR representative, the Caremark benefit portal, or SEHP directly ^[1]. The sources reviewed do not specify how many members are affected or provide exact cost figures behind the decision, so the scale of the change and its financial details are not yet known from what SEHP has published.